A phase Ib study of oxaliplatin in combination with fluorouracil (5FU) and leucovorin (LV) in pediatric patients (pts) with advanced solid tumors

被引：0
|
作者：
Gore, L.
Kuttesch, J.
Hunger, S. P.
Herzog, C.
Narendaren, A.
Boklan, J.
Foreman, N. K.
Ivy, S. P.
Boucher, N.
Trippett, T. M.
机构：
[1] UCHSC Fitzsimons, Aurora, CO USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Univ Florida, Shands Canc Ctr, Gainesville, FL USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Calgary, Alberta Childrens Hosp, Calgary, AB, Canada
[6] Phoenix Childrens Hosp, Phoenix, AZ USA
[7] NCI, Rockville, MD USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9548
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A randomised phase II study comparing irinotecan (IRI) plus leucovorin (LV) and 5-fluorouracil (5FU) versus IRI-LV-5FU followed be oxaliplatin (OXA) plus LV-5FU in patients with previously untreated metastatic colorectal cancer (CRC).
    Kalofonos, H. P.
    Papakostas, P.
    Aravantinos, G.
    Papadimitriou, C.
    Pentheroudakis, G.
    Varthalitis, I.
    Tsavdaridis, D.
    Syrigos, K.
    Kosmidis, P.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [32] A Phase I study of hepatic arterial infusion of oxaliplatin in combination with systemic fluorouracil, leucovorin and bevacizumab in patients with advanced solid tumors metastatic to the liver
    Tsimberidou, Apostolia
    Hong, David
    Ng, Chaan
    Wheler, Jennifer
    Naing, Aung
    Bedikian, Agop
    Eng, Cathy
    Fortier, Adoneca
    Uehara, Cynthia
    Kurzrock, Razelle
    CANCER RESEARCH, 2009, 69
  • [33] Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC):: CALGB 80203 preliminary results.
    Venook, A.
    Niedzwiecki, D.
    Hollis, D.
    Sutherland, S.
    Goldberg, R.
    Alberts, S.
    Benson, A.
    Wade, J.
    Schilsky, R.
    Mayer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 148S - 148S
  • [34] Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
    Cho, CD
    Fisher, GA
    Halsey, J
    Sikic, BI
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (02) : 117 - 123
  • [35] Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
    Cheryl D. Cho
    George A. Fisher
    Joanne Halsey
    Branimir I. Sikic
    Investigational New Drugs, 2006, 24 : 117 - 123
  • [36] Phase I Trial of Sorafenib in Combination With 5-Fluorouracil/Leucovorin in Advanced Solid Tumors
    Shacham-Shmueli, Einat
    Geva, Ravit
    Figer, Arie
    Bulocinic, Sarah
    Nalbandyan, Karen
    Shpigel, Shulim
    Atsmon, Jacob
    Brendel, Erich
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 656 - 669
  • [37] TREATMENT OF ADVANCED GASTRIC-CANCER WITH METHOTREXATE (MTX), 5-FLUOROURACIL (5FU), LEUCOVORIN (LV), CISPLATIN (DDP)
    BRUCKNER, HW
    SUNG, MW
    CHESSER, M
    WONG, H
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 203 - 203
  • [38] A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-fluorouracil in patients with advanced solid tumors
    Souglakos, J
    Kakolyris, S
    Vardakis, N
    Androulakis, N
    Mavroudis, D
    Vamvakas, L
    Kouroussis, C
    Agelaki, S
    Saridaki, Z
    Georgoulias, V
    CANCER INVESTIGATION, 2005, 23 (06) : 505 - 510
  • [39] CONSECUTIVE EXPERIENCE OF PHASE-I-II WITH THE COMBINATION OF FOLINIC ACID (AF) AND 5-FLUOROURACIL (5FU) IN PATIENTS (PZ) WITH ADVANCED SOLID TUMORS
    DIBLASIO, B
    BELLA, M
    BISAGNI, G
    BACCHI, M
    LOTTICI, R
    BONI, C
    CECI, G
    DELISI, V
    PASSALACQUA, R
    COCCONI, G
    TUMORI, 1986, 72 (06) : 704 - 704
  • [40] Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study.
    Iqbal, S
    Cole, S
    Yang, D
    Lara, PN
    Gumerlock, PH
    Shibata, S
    Synold, T
    Doroshow, JH
    Gandara, D
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 141S - 141S
12345